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A B S T R A C T 
Understanding the molecular programs of the generation of human dopaminergic neurons 
(DAn) from their ventral mesencephalic (VM) precursors is of key importance for basic studies, 
progress in cell therapy, drug screening and pharmacology in the context of Parkinson's disease. 
The nature of human DAn precursors in vitro is poorly understood, their properties unstable, and 
their availability highly limited. Here we present positive evidence that human VM precursors 
retaining their genuine properties and long-term capacity to generate A9 type Substantia nigra 
human DAn (hVMl model cell line) can be propagated in culture. During a one month 
differentiation, these cells activate all key genes needed to progress from pro-neural and pro-
dopaminergic precursors to mature and functional DAn. For the first time, we demonstrate that 
gene cascades are correctly activated during differentiation, resulting in the generation of 
mature DAn. These DAn have morphological and functional properties undistinguishable from 
those generated by VM primary neuronal cultures. In addition, we have found that the forced 
expression of Bcl-XL induces an increase in the expression of key developmental genes (MSX1, 
Abbreviations: A9-DAn, (dopaminergic neuron from the A9 group); 6-OHDA, (6-hidroxydopamine); DA, (dopamine); 
DAn, (dopaminergic neuron); FB, (forebrain); FP, (floor plate); hESC, (human Embryonic stem cells); hNSC, (human neural stem cells); 
hVM, (human ventral mesencephalon); SNpc, (substantia nigra pars compacta); TH, (tyrosine hydroxylase); VM, (ventral mesencepha-
lon); VM DAn, (dopaminergic neuron from ventral mesencephalon); VM hNSC, (human neural stem cells from ventral mesencephalon) 
NGN2), maintenance of PITX3 expression temporal profile, and also enhances genes involved in 
DAn long-term function, maintenance and survival (ENl, LMXIB, NURRl and PITX3). As a result, 
Bcl-XL anticipates and enhances DAn generation. 
Introduction 
Dopaminergic neurons (DAn) of the ventral mesencephalon (VM) 
play essential roles in reward-based behaviors and control of 
voluntary movement, and the progressive loss of DAn from the 
A9 group (A9-DAn) of the Substantia nigra pars compacta (SNpc) 
causes motor impairments characteristic of Parkinson's disease 
(PD) [1,2]. Much effort has been done to identify the precursors 
of VM DAn and to understand the genetic cues and cascades 
controlling the development of VM DAn in experimental animals 
and humans. Such knowledge has the potential to improve the 
capacity to generate or engineer correctly differentiated human 
A9-DAn in vitro from their stem/precursor cells, and use them for 
basic studies, pharmacological drug screening and the develop-
ment of cell replacement therapies [3-8]. 
VM DAn originate from precursors residing in the mesence-
phalic floor plate (FP), both in rodents and humans, which show 
features of radial glia [9-12], reviewed by [6,13-24]. In spite of 
the importance of identifying a well-characterized and reliable 
source of human A9-DAn, the present situation is that all neural 
stem/precursor cultures explored so far present numerous lim-
itations. In addition, there is a large controversy on the actual 
capacity of various cultures derived from the fetal human VM to 
generate A9-DAn, in a stable manner [8,25-29]. In parallel to the 
work with non-immortal precursor cells, several groups, includ-
ing ours, have recently developed immortalized cell lines of 
human neural stem/precursor cells (hNSCs), some of them 
derived from the fetal human VM (MESC2.10, NGC-407, ReNcell 
VM, vm c-mycER™ and hVMl) [30-34]. In these model cell lines, 
the non-transforming, immortalizing gene, v-myc overcomes the 
problem of limited expansion. The knowledge on the properties 
of the precursors being expanded in these cell lines, the 
preservation of their regional specification, and their capacity 
to activate correct genetic developmental programs, is very 
limited and uncertain, so far. In the present work, and using 
the hVMl cell line as a model system, we have mainly aimed at 
defining in detail the molecular properties of, and the develop-
mental steps taken by VM hNSCs when differentiating to A9-DAn 
(one month, long-term differentiation). This constitutes an 
essential step to fully understand the nature of the cells, and 
the means to proliferate them and preserve their neurogenic 
capacity. 
In addition, we have investigated the potential effects that the 
forced expression of Bcl-XL may have on the properties of hVMl 
cells and on their differentiation. The capacity of hNSCs and of 
human embryonic stem cells (hESCs) to generate DAn displaying 
the correct A9 phenotype is enhanced by Bcl-XL [35-37]. 
Although a survival effect was attributed to Bcl-XL in both 
systems, the enhanced expression of transcription factors related 
to DAn development has been investigated in the present 
work, to better understand Bcl-XL actions in VM hNSCs (hVMl 
cells). Such knowledge will increase our understanding of the 
instability of VM precursor cells' properties in vitro, expand on 
the non-antiapoptotic functions of Bcl-XL and help to replace its 
use with other interventions that would not pose safety hurdles, 
since blocking apoptosis could drive the cells closer to uncon-
trolled growth. 
Materials and methods 
Cell culture 
VM hNSCs isolation, immortalization, culture, Bcl-XL forced 
expression and ethics permissions were previously described 
[34,36]. Briefly, the hVMl cell line was generated from VM tissue 
of a 10 weeks post-conception old human fetus by v-myc 
immortalization [34]. Low passage number hVMl cells were 
further modified to over-express Bcl-XL [36]. The polyclonal cell 
lines naive hVMl and the ones with the forced expression of 
Bcl-XL are referred here as control or Bcl-XL hVMl cells. Detailed 
cell culture methods are provided under Supplementary infor-
mation. Experiments were carried out using hVMl cells at 
passage 9 to 12, and Bcl-XL cells at passages 25-30, in order to 
work with cells with similar neurogenic potential (see the 
Results section). Mouse primary neuron cultures were obtained 
from VM of E12-E14 mice, following procedure detailed in [38]. 
RNA extraction and Q-RT-PCR 
Total RNA was isolated from proliferating or differentiated cells 
using high pure RNA isolation kit (Roche, Basel, Switzerland). The 
cDNA was synthesized from 1 p,g of RNA using the high capacity 
cDNA Achieved kit (applied biosystems, Carlsbad, CA). Relative 
quantification of RNA expression was performed by TaqMan real 
time PCR using commercial probes described in Supplementary 
information, and was performed using the ABI PRISM 7900 
HT Sequence Detection System as detailed in [36]. Calibrator 
samples to study the temporal expression profile of each gene in 
each cell line were day 0 (dO) samples. To study differences in the 
expression of a given gene between control and Bcl-XL cells, 
hVMl at dO was taken as the calibrator sample and results are 
shown as the ratio hVMl Bcl-XL/hVMl. The relative expression of 
a gene with respect to that of TH was defined as (gene of interest 
RQ/TH RQ). All Q-RT-PCR data were obtained from biological 
triplicates, each run three times (technical triplicates). 
Immunocytochemistry (ICC) and western blotting (WB) 
Samples were processed following standard protocols [34,36] 
and using antibodies described in Supplementary information. 
Morphometric analysis 
Neurite's morphology of TH+ cells in cultures differentiated for 
12-30 day was analyzed as described [39]. A minimum of 50 TH+ 
cells was photographed in randomly chosen fields for each 
sample and analyzed using NeuronJ/ImageJ (NIH, USA). The cell 
and processes were semi-automatically traced and assigned the 
status of primary, secondary, tertiary or quaternary neurites. 
Electrophysiology 
Functional properties of differentiated hVMl Bcl-XL cells were 
evaluated by the whole-cell patch-clamp technique as described 
previously [40]. In short, cover slips with attached differentiated 
cells were transferred to a recording chamber continuously 
perfused at a rate of 3 ml/min, at room temperature, with 
carbogenated (95% 02/5% C02) artificial cerebrospinal fluid 
(aCSF). Resting membrane potential (RMP) was measured in 
current-clamp mode at 0 pA. Input resistance (R¡) was assessed 
from 5 mV square voltage pulses at RMP. For current/voltage 
(¡IV) relationship curves, we measured the membrane potential, 
while injecting 500 ms positive or negative currents stepwise. In 
some experiments tetrodotoxin (TTX, 2 uM) was added to the 
perfusion medium to confirm that action potentials were sodium 
channel-dependent. All data are presented as mean + standard 
error of the mean (SEM). Analyses for temporal changes were 
done by linear regression tests. Level of significance was set at 
p<0.05. 
Activity assays of dopamine transporter (DAT) 
Dopamine reuptake 
Thirty-days differentiated control or Bcl-XL hVMl cells and 
mouse VM primary neuronal cultures (El2, C57/BL6 mice, 
maintained for 1 week) were used to measure dopamine trans-
port. Nomifensine (NMF, lOuM, Sigma), a DAT inhibitor, was 
used to block unspecific transport. Cells (plus/minus NMF) were 
incubated with 50 nM [3H]-DA (di-hydroxy-phenylethylamine 
3.4—(ring-2,5,6-3H), 30-60 Ci/mmol, PerkinElmer, Waltham, 
MS) for 30 min at 37 °C. The reaction was stopped by removing 
the medium and washing the samples twice with PBS. Cells were 
lysed with 0.5 M NaOH and 0.2 ml scintillation cocktail was 
added per well. 
Live cells imaging with 4-di-2-ASP 
ASP+ (4-(-(diethylamino) stiril)-JV-methylpyrimidine iodide) is a 
fluorescent analog of l-methyl-4-phenyl pyrimidine, a well-
studied neurotoxin transported by monoamine transporters. 
NMF was used to prevent binding to DAT in control samples. 
Cells were incubated with 0.5 uM ASP+ (Invitrogen, Carlsbad, CA) 
for 15 min at 37 °C, and extensively washed with modified 
Tyrodes' solution. Trypan Blue (30 uM, Sigma) was added to 
the medium to reduce autofluorescence. Live cell images were 
collected using a confocal LSM510 inverted microscope coupled 
to an Axiovert200M (Zeiss) optical microscope. Fluorescence 
images (488 nm excitation, 607 nm emission) were mounted 
off-line onto the corresponding bright field images. 
Treatment of cultures with 6-hydroxydopamine (6-OHDA) 
Differentiated (30 d) control and Bcl-XL hVMl cells were treated 
with 50 mM 6-OHDA (Sigma) in the presence or absence of 
10 uM NMF (Sigma) for 1, 2 or 3 days. Afterwards, the cells were 
fixed and immunostained for TH to assess the percentage of 
surviving DAn. TH+ cells were counted in an Axiovert200 
microscope (Zeiss) at 40 x . 
Statistical analyses 
All data are shown as means + SEM of at least three independent 
experiments. Data were analyzed by ANOVA followed by the 
appropriate post-hoc test (Instat 2.03, Graph Pad Software). 
Results 
Forebrain and VM hNSCs preserve their different regional 
information 
Preservation of the regional properties in long term-cultured 
hNSCs is not granted. Therefore, the expression levels of two very 
early neuroectoderm markers (PAX6, EN1) and of SNpc genes 
(TH, DAT, GIRK2) were studied in FB and VM hNSCs (human 
neural stem cells) (Fig. 1A). PAX6, a determinant of neuroecto-
derm fate, was expressed at higher levels in FB than in VM cells. 
EN1, a transcription factor characteristic of the midbrain neu-
roepithelium, was expressed at two orders of magnitude higher 
levels in hVMl than in hNSl cells. In parallel, TH and DAT 
expression was substantially higher in hVMl cells, and, most 
importantly, GIRK2 expression, typical of A9 DA neurons, was 
differentially expressed at much higher levels in VM than in FB 
cells. hVMl cells also expressed OTX2 and SOX2 (Supplementary 
information Fig. 1). 
We have reported that DAn generation from VM hNSCs 
decreases with passaging, and that neurogenesis is enhanced 
and stabilized after forced expression of Bcl-XL [35,36,41,42]. 
Since in the present study we wanted to work with hNSCs 
producing neurons (|3-III-tubulin+) at the same rate, to focus on 
the dopaminergic phenotype, we chose to work with different 
passage numbers of control and Bcl-XL hVMl cells (9-12 and 
25-30, respectively), generating in each case approximately 20% 
neurons (|3-III-tub+, Fig. IB and C). In the same cultures, the rate 
of TH+ neuron generation was increased in Bcl-XL cells in 
comparison to control ones by 30% at d7 and 100% (2-fold) at 
d30 of differentiation (Fig. 1C). The cholinergic (ChAT+) pheno-
type was not detected throughout the experiment and seroto-
nergic (5-HT+) neurons were only occasionally found (less than 
0.01%). As expected for VM precursors, the cultures generated 
4.05%+0.56 GABA+ and 1.94%+0.26 Glutamate+ neurons. 
Expression of proneural genes at early differentiation 
times 
In FB hNSCs mitogen withdrawal triggers differentiation, and 
thus the percentage of nestin and Ki-67 positive cells decreases 
to about 20% by d7 [42]. In hVMl cells, differentiation is 
accompanied by the disappearance of nestin+ cells (NSCs), and 
the exit of the majority of the cells in culture from the cell cycle 
(becoming Ki-67 negative) (Supplementary information Fig. 2). 
Bcl-XL did not induce any significant change at any time point or 
marker studied, but for a trend for a faster disappearance of 
nestin+ cells. 
Simultaneously, during the first week of differentiation, the 
human homologues of three proneural genes known to have 
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Fig. 1 - Regional identity and basic phenotypical properties of hVMl cells. (A) Q-RT-PCR of genes related to central nervous 
system regionalization. Results are mean+SEM (n=3) (*p<0.05, **p<0.01, ***p<0.001, compared to hNSl dO; t-test). (B) 
Immunocytochemical staining for p-III-Tubulin (green) and TH (red) in 30 day differentiated hVMl and hVMl Bcl-XL cultures. 
Nuclei were visualized by ToPro3 staining (blue) (scale bar=20 um). (C) Percentage of p-III-Tubulin+ and TH+ cells from total 
cells in differentiated cultures. Note the decrease in both neurons and TH+ neurons from d7 to d30 in control hVMl cells. Data 
were obtained from triplicate experiments and are expressed as mean+SEM. Stats: ANOVA followed by post-hoc Tukey test (p-III-
Tubulin; *p<0.05, vs d7) and t-test Welch correction (TH; ***p<0.001 vs d4;+i-<0.01,+H-p<0.001 hVMl vs hVMl Bcl-XL at the 
indicated day; §§§ p< 0.001 vs previous day for each cell line). (For interpretation of the references to color in this figure legend, 
the reader is referred to the web version of this article.) 
crucial roles in the development of midbrain neurons in the 
mouse (Mashl, Msxl and Neurogenin2 (Ngn2)) have been studied 
(Fig. 2). Whereas Mashl is a general proneural gene, thought to 
act in a permissive manner (that is, dispensable, not required nor 
sufficient for DAn generation), Msxl and Ngn2 are essential for 
the correct development of VM DAn [6,17,18,23,27,43-47]. 
A) Temporal expression (data from each cell type compared to 
levels at dO): We have previously shown that MASH1 and 
NGN2 expression become activated with differentiation in 
control hVMl cells [34]. Here (to assure consistency between 
studies) we have reproduced those findings (activation of 
MASH1 expression and the transient expression of NGN2 
(peaking at d4) in hVMl control cells) (results not shown). In 
the case of MSX1, parallel to MASH1, there is an increase in its 
expression along a one-week differentiation in control cells 
(Fig. 2A). In Bcl-XL cells the time course of expression of 
MASH1 and NGN2 was unaltered, but there was a clear 
anticipation of the peak levels of MSX1 (by d4). 
B) Net Bcl-XL effects on gene expression levels: When the expres-
sion data were compared at each day being Bcl-XL the only 
variable (Fig. 2B) we found that there was an one order of 
magnitude enhancement of NGN2 levels present at dO and d7 
(not shown, see also Ref. [34]), and that MSX1 levels were 
significantly increased around 15-fold by Bcl-XLat d4, what may 
be determinant for an enhanced DAn generation. 
Expression of pro-dopaminergic transcription factor 
genes at early differentiation times 
EN1, LMX1B, NURR1 and PITX3 are needed for the correct 
development of VM A9-DAn [6,17], and were studied in parallel 
to TH (tyrosine hydroxylase, the rate limiting enzyme in cate-
cholamine biosynthesis; serving here as a reporter of the 
presence of DAn). 
A) Temporal expression (data from each cell type compared to 
levels at dO): All studied genes, but PITX3, showed a similar 
time course of expression between the control and Bcl-XL cells 
(Fig. 3A). EN1 expression remained nearly constant during the 
one week of differentiation, as expected, whereas LMX1B, 
NURR1 and TH progressively increased their expression levels 
in both cell types, consistent with the earlier expression of 
proneural genes (Fig. 2). Note that the expression levels of 
LMX1B, NURR1 and PITX3 by d4 are only different from those at 
dO in the Bcl-XL cells. The case of PITX3 was interesting since the 
control cells expressed it, but did not up-regulate the gene, even 
by d7 (and even later, see below). This aspect could be 
important to explain a lower yield of DAn in the control 
cultures, when compared to Bcl-XL ones. 
B) Net Bcl-XL effects on gene expression levels: When the 
expression data were compared at each day being Bcl-XL 
the only variable (Fig. 3B) we found a number of interesting 
differences between control and Bcl-XL cells. First, as 
expected from the increased number of TH+ neurons in Bcl-
XL cells at d7 (Fig. 1C), we observed a «4-fold increase in TH 
mRNA levels induced by Bcl-XL. This was accompanied and 
possibly explained by the increased levels of all other genes in 
Bcl-XL cells: EN1 («1.5-fold by dO), LMX1B («5-fold by d7), 
NURR1 («2-fold by d7) and particularly PITX3 («10-fold 
enhancement by d4, just the time when its expression is 
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Fig. 2 - Expression of proneuronal genes during early 
differentiation times. (A) Temporal gene expression profile 
of MSX1 in each cell line determined by Q-RT-PCR (see legend 
of Supp. Info. Fig. 1 for detailed calculations). Results are 
mean+SEM (n=3) (*p<0.05, ***p<0.001 vs dO; t-test). (B) 
Bcl-XL effects on relative MSX1 mRNA levels expressed as ratio 
hVMl Bcl-XJhVMl at each studied day (see legend of Supp. 
Info. Fig. 1 for detailed calculations). Results are mean+SEM 
(n=3) (*p<0.05, indicates significant differences to 1 (equal 
values); one sample t-test). 
needed, to cooperate in the generation of DAn). Note that by 
d4 of differentiation TH+ neurons are starting to appear in the 
cultures («1-2% in the case of control hVMl cells [34], 
Fig. 1C). 
DAn generated from hVMl hNSCs produce and release DA after 
depolarization [34-36], both in the presence and absence of 
elevated Bcl-XL levels. For a TH+ neuron to synthesize DA, at least 
two other enzymes are needed, aromatic aminoacid de-carbox-
ylase (AADC), and GTP-Cyclohydrolase I (GTPCH, needed for the 
synthesis of the TH cofactor tetra-hydro-biopterin (BH4)). As 
shown in Supplementary information Fig. 3 both genes are 
expressed in control and Bcl-XL cells. Their expression levels 
increased during the first week of differentiation in control hVMl 
cells, whereas AADC increased and GTPCH remained nearly 
constant for Bcl-XL cells (Supplementary information Fig. 3A). 
When the expression data for these two genes were referred to 
those of TH (Supplementary information Fig. 3B) we found that 
their expression levels were significantly higher in Bcl-XL cells 
when compared to control hVMl ones, suggestive of an 
increased dopaminergic phenotype of the latter (for a given TH 
level). The expression of Dopamine-|3-hydroxylase (DBH), which 
converts DA further into noradrenaline and adrenaline, present 
in TH+ adrenergic neurons, was not detected by Q-PCR even after 
40 cycles of amplification. 
Long term differentiation and expression of maturation, 
function-related genes 
As shown in Fig. 1, the number of neurons and TH+ neurons does not 
increase with differentiation time beyond d!2 of differentiation. To 
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study the maturation of the DAn long-term (up to d30), we selected 
four genes that must be co-expressed with TH in a functional DAn: 
dopamine transporter (DAT), vesicular monoamine transporter 2 
(VMAT2), dopamine receptor subtype 2 (DRD2), and the G-protein 
coupled inwardly rectifying K channel (GIRK2, almost exclusive of 
A9-DAn). 
(A) Temporal profile: TH mRNA levels peaked at dl2 in control 
cells, decreasing afterwards (Fig. 4Ai), in parallel to TH+ 
neurons (Fig. 1C); opposite, the four function-related genes 
continued increasing their expression during the month 
studied (Fig. 4B). This points to a long differentiation time 
required by TH+ neurons to become functionally active (as 
proposed in [26,40,48]). In the case of Bcl-XL cells, the time 
course of expression was notoriously different, since DAT, 
VMAT and DRD2 expression peaked at dl2 instead of d30 
(Fig. 4B). This might be suggestive of the DAn maturing faster 
in the presence of elevated levels of Bcl-XL. 
(B) Net Bcl-XL effects on gene expression: TH expression was 
enhanced 2-fold in Bcl-XL cells by d30 (Fig. 4Aii), in parallel to 
TH+ neurons (Fig. 1C). For DAT, VMAT2, DRD2 and GIRK2, the 
ratio of expression in the presence or absence of increased Bcl-XL 
levels (data treated as in Fig. 2B and Fig. 3B, ratio Bcl-XL to 
control cells) did not reveal any relevant changes (results not 
shown). When expression data of the four genes in each cell line 
were normalized to TH levels (an indication of their DA pheno-
type), we found that Bcl-XL did not make the neurons more 
mature per unit of TH expression (Fig. 4C), but prevents the 
decrease in expression of these genes observed in control cells by 
d30. Similar results were obtained after WB or ICC determina-
tions shown in Fig. 4D and E, showing that by d30 there is more 
TH protein or cells in the case of Bcl-XL cultures, an enhancement 
that is accompanied by the increased presence of the other four 
proteins. 
Long-term expression of transcription factors required for 
function and survival 
Recent studies have proposed a maintenance and survival role 
for some of the factors studied here (EN1, LMX1B, NURR1 and 
PITX3), in addition to their known developmental roles [49-55] 
(reviewed in [6,15,49]). We therefore analyzed their expression 
in 30d-differentiated control and Bcl-XL hVMl cells. When 
referring expression data to the level at dO, in control cells, 
NURR1 was the only gene expressed long term at slightly higher 
levels than in non-differentiated cells, whilst EN1 and LMX1B 
expression returned to basal levels (Fig. 5A) (PITX3 never got 
activated, see Fig. 3). In sharp contrast, the forced expression of 
Bcl-XL yields cultures where most genes were expressed long-
term at higher levels than in dividing cells (10-40 fold enhance-
ment) (EN1 is slightly below levels seen at dO, 0.86-fold) 
(Fig. 5A). The net fold enhancement of transcription levels 
induced by Bcl-XL (Fig. 5B) was 20-50 folds for LMX1B, NURR1 
and PITX3, and 1.42-fold for EN1. This enhancement cannot be 
attributed solely to a survival action of Bcl-XL since TH+ neurons 
only increased 2-fold (Fig. 1C). 
Morphological and functional long-term maturation of 
the DAn 
A detailed morphometric account of the shape and arborization 
of the TH+ neurons after differentiation oh hVMl cells, and of 
Bcl-XL effects on these parameters, has not been previously 
undertaken. To this end, we differentiated the cultures for one 
month (plus/minus forced expression of Bcl-XL), and studied 
their evolution. To challenge the human system, we used as a 
control the best possible counterpart, a primary neuronal culture 
derived from fetal mouse VM. The results in terms of soma size, 
and the type, number and length of neurites present in the TH+ 
neurons are summarized in Fig. 6. Similarly to primary neurons, 
in control and Bcl-XL hVMl cells we found mid size neurons with 
ovoid, polygonal or fusiform morphology, typical of A9-DAn. 
Neurons were bi- or multi-polar, and the mean soma area was 
not different between primary neurons and those derived from 
control or Bcl-XL hVMl cells (Fig. 6A and B). Details of all 
parameters studied for each cell type, times of differentiation 
and neurite order are provided in Supplementary information 
Fig. 4. The number of each type of neurite (Fig. 6C) and their 
average length (Fig. 6D) at d30 of differentiation, overall show 
that the neurite number seem to be lower in the order primary 
culture>hVMl>hVIVIl-Bcl-XL, whereas neurite length gets 
compensated showing values that increase in the order 
hVMl-Bcl-XL>hVMl > primary cultures. One may then con-
clude that the degree of arborization (Fig. 6E) is rather similar 
between primary and hVMl derived TH+ neurons, the most 
noticeable difference being a reduction at d30 to approximately 
one half in Bcl-XL derived neurons. 
Control hVMl cells differentiate into functional neurons, 
according to calcium handling and electrophysiological para-
meters [40]. Since electrophysiological properties of SNpc are 
well established, here we only studied differentiated cultures of 
Bcl-XL hVMl cells. Twenty-six of forty-nine cells that were 
analyzed electrophysiological displayed early neuronal proper-
ties, including broad, relatively immature action potentials that 
where blocked by the sodium channel blocker TTX, and rectifica-
tion of membrane currents (Fig. 7A and B). Electrophysiological 
evaluation, at d4 to dl3 of differentiation, did not reveal any 
changes over time in input resistance (R¡) or resting membrane 
potential (RMP), though some tendency for an increase of RMP 
was apparent (Fig. 7C and D). The overall RMP average for the 
whole population of neurons over all time points was -48.2 mV 
and the R, was 1404 + 188 Mil The remaining population of the 
recorded cells (23 cells) displayed passive membrane properties 
and a lower R, at 111+12.6 Mil and was considered as of a glial 
identity (Fig. 7E). The differences in membrane resistance and 
lack of presence of membrane rectifying properties allowed for 
very clear discrimination between neuronal and non-neuronal 
cell populations (Fig. 7F). 
In summary, both control [40] and Bcl-XL hVMl cells (present 
work) differentiate in vitro exhibiting electrophysiological prop-
erties indicative of both neuronal and glial phenotypes. Electro-
physiological neuronal characteristics of both cell lines indicate 
that DAn neurons that are part of the neuronal population show 
immature action potential, relatively depolarized resting mem-
brane potential, and properties typical of A9 DAn like high input 
resistance (2000 MCI), and broad, low amplitude action poten-
tials. Slow electrophysiological maturation, requiring up to 6 
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Fig. 4 - Expression studies of genes related with functional maturation of DAn. (A) TH expression during long-term 
differentiation. (Ai) Temporal TH mRNA expression profile determined by Q-RT-PCR Data from each cell line was normalized 
to its own calibrator sample (value at dayO, set as value 1; for further details see the Materials and methods section, and the 
legend for Supplementary Fig. SI). Results are mean+SEM (n=3) (**p<0.01, ***p<0.001 vs d0;+fp<0.01 vs previous day; t-test). 
(Aii) Bcl-XL effects on TH relative mRNA levels expressed as the ratio hVMI Bcl-XJhVMl at each studied time. Results are 
mean+SEM (n=3) (**p<0.01 indicates significantly from 1 (95% confidence interval), one sample t test). (B) Temporal DAT, 
VMAT2, DRD2 and CIRK2 mRNA expression profile determined by Q-RT-PCR at dO, dl2 and d30 of differentiation. Results are 
mean+SEM (n=3) (**p<0.01, ***p<0.001 vs dO; +p<0.05, ++p<0.01 vs previous day; t-test). (C) Comparative expression level 
of genes related to dopaminergic system vs TH relative expression determined by ratio calculations (see Supp. Inf. Figs. 1 and 3 
for more details). Results are mean+SEM (n=3) (*p<0.05, **p<0.01, ***p<0.001 indicate that the mean differs significantly 
from 1 (95% confidence interval), one sample t-test); +H-p<0.001 dl2 vs d30 (t-test). (D) Protein expression studies by 
immunoblots. The WBs show TH, VMAT2, DAT and CIRK2 protein levels in hVMI and hVMI Bcl-XL cells differentiated for 30 day. 
P-actin was used as loading control. (E) hVMI and hVMI Bcl-XL were analyzed by ICC at d30 of differentiation, detecting 
expression of TH, DAT, VMAT2 and DRD2 (red). These proteins colocalize with TH+ cells (green). Nuclei were counterstained using 
ToPro3 (blue) (scale bar=20 um). (For interpretation of the references to color in this figure legend, the reader is referred to the 
web version of this article.) 
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Fig. 5 - Long term expression of dopaminergic transcription factors involved in maintenance and survival (A) Relative mRNA 
expression level of EN1, LMXlb, NURR1 and PITX3, at d30 of differentiation. Results are mean+SEM (n=3) (*p<0.05, ***p<0.001 
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mean+SEM (n=3) (*p<0.05, **p<0.01 indicate a significant difference from value 1 (95% confidence interval), one sample t test). 
weeks of differentiation, has also been reported for human 
telencephalic precursor-derived neurons in vitro [56]. 
Another functional property of interest is the ability of the 
differentiated cultures for DA uptake, mediated by functional 
DAT. Positive evidence for a functional DA transport not only 
adds on the functionality of the neurons, but also comes to 
validate the Q-RT-PCR data shown in previous sections (Fig. 4). 
First, we studied ASP transport and accumulation (Fig. 8A), what 
indicated a clear NMF-sensitive accumulation in primary cul-
tures, and in control and Bcl-XL hVMl differentiated cultures. 
Second, we studied the NMF-sensitive 6-OHDA-induced TH+ 
neuronal death (Fig. 8B) finding that 6-OHDA kills a substantial 
fraction of the TH+ neurons generated in these cultures, but not 
in the presence of NMF, meaning that it was induced by toxin 
accumulation via DAT-mediated transport (and not by unspecific 
6-OHDA toxicity caused by auto-oxidation). And thirdly, we 
measured the actual transport of [3H]-DA, finding no differences 
in the NMF-sensitive transport per TH+ cell in the three types of 
cultures (Fig. 8C). In conclusion, from the point of view of the 
presence and activity of a functional DAT, there are no differ-
ences between the DAn generated by a primary fetal neuronal 
culture and those generated by control or Bcl-XL hVMl cells. 
Discussion 
When large numbers of identical neurons are required, as for 
drug testing or to complete a clinical trial, a continuous and 
stable source of genuine A9-DAn is needed. The present scenario 
is challenging since the capacity of human fetal VM precursor 
cultures to generate A9-DAn is controversial [8,28,29]. Human 
VM neurospheres show a limited expansion capacity, cease to 
yield DAn (and neurons) with passaging in culture, and in some 
cases the few DAn present are not born in culture [26,57-59], 
phenomena also described in rodents [25,60,61]. Adherent 
human VM FP radial glia cultures cells have been described to 
maintain their neurogenic potential, but do not differentiate into 
DAn [20]. Therefore, effort has been put on interventions aimed 
at enhancing neuron generation [26,58,62]. In the end, there 
exists the uncertainty of whether or not patterned precursors for 
human A9-DAn can be propagated in culture while retaining 
proper cell intrinsic information. In parallel to the work with 
primary cultures, several groups have developed immortalized 
hNSC lines derived from the fetal human VM (MESC2.10, 
NGC-407, ReNcell VM, vm c-mycER™ and hVMl, Refs. [30-34]). 
However, their properties and capacity to activate correct devel-
opmental programs, has remained largely unexplored or uncer-
tain. In most cases only nestin and TH expression have been 
reported. 
Regionalization and activation of developmental gene 
cascades in hVMl precursor cells 
The proposition that regionally specified precursors can be 
propagated long-term in culture implies that the cells must 
retain their patterning, which is not granted. Patterning 
preservation has been demonstrated in cortical, striatal and 
midbrain neurospheres [57,58,63], but there is only indirect 
evidence for FB or VM v-myc hNSC lines [34-36,40-42,64], and 
the cell lines have never been studied head-to-head. In the 
present work we first clarified that long-term cultured FB and 
VM hNSCs differentially express early neuroectodermal markers 
(PAX6, EN1), and generate neurons showing differential expres-
sion of A9-DAn genes (such as GIRK2) (Fig. 1A). In the mouse 
embryo, Pax6 is expressed in the neuroectoderm of the FB and 
hindbrain [64]. In human stem cells PAX6 acts as a determinant 
of neuroectoderm fate [65-67]. Consistently, some expression 
was detected in hVMl cells, but it was higher in hNSl cells 
(Fig. 1A). EN1, characteristic of the midbrain neuroepithelium, 
and TH, DAT and GIRK2 expression were substantially higher in 
hVMl cells, as compared to hNSl ones. OTX2, involved in the 
positioning of the midbrain/hindbrain boundary, maintenance of 
precursor domains, and precursor proliferation and maturation 
[6,9,17,45,68] was also expressed in hVMl cells (Supplementary 
information Fig. 1). Altogether, these data not only indicate the 
persistence of a developmental program and patterning preser-
vation, but also identify the hVMl cells as neural stem cells 
showing most features of FP VM precursors for A9-DAn (expres-
sion of midbrain developmental genes (EN1, OTX2), neuroepithe-
lial genes (SOX2), early midbrain and dopaminergic genes such 
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Fig. 6 - Morphometric analysis of dopaminergic neurons. Measurement of different parameters of TH+ cells in primary fetal (E12) 
mouse VM cultures, hVMl and hVMl Bcl-XL cells after long-term differentiation. hVMl and hVMl Bcl-XL were differentiated for 
30 day, and VM control cultures were maintained 22 day in vitro. (A) ICC for TH (red) and nuclear stain (blue, ToPro3). Snapshots 
taken with NeuronJ plug-in show semi-automatically traced neurites in different colors (see legend) in four analyzed neurons 
per picture (scale bar=40 fim). (B) Cell body area was calculated by ImageJ and expressed as mean+SEM (n> 10, ANOVA, post-hoc 
Tukey test). (C) Average number of each neurite type per TH+ cells. Results were expressed as mean+SEM (n>50), (*p<0.05, 
**p<0.01 vs VM culture; +p<0.05 hVMl vs hVMl Bcl-XL cells; Kruskal Wallis test). (D) Average length of each type of neurites 
present in TH+ cells expressed as mean+SEM (n>50), (*p<0.05, **p<0.01 indicate significant differences with VM culture; 
Kruskal Wallis test). (E) Total arborization (neurite length). Results are expressed as mean+SEM (n>50), (*p<0.05, ***p<0.001 
vs dl2; +p < 0.05,+ip< 0.01,+H-p< 0.001 vs VM culture at each day; 000p< 0.001 hVMl vs hVMl Bcl-XL at each day; ANOVA, post-
hoc Tukey test). 
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Fig. 7 - Electrophysiological properties of differentiated hVMl Bcl-XL cells. (A) Twenty-six of 49 recorded cells were characterized 
as neuronal based on rectification of the membrane voltage in response to stepwise current injections and on firing of immature 
action potentials in response to current injections. (B) Immature action potentials were blocked in the presence of the sodium 
channel blocker TTX. (C) The input resistance of recorded neuronal cells did not change over the measuring period. (D) A 
tendency for an increase in the membrane potential could be observed among the neuronal cells during the measuring period, 
though this did not reach significance. (E) Example of voltage response of passive cell classified as non-neuronal. No rectification 
or active membrane properties can be observed in response to positive and negative current injection steps at 20 pA increments. 
(F) Current/voltage curves of the neuronal and the passive cell populations, illustrated as the resting membrane potential (RMP) 
dependency on current injections. The different membrane properties of the neuronal and noneuronal, passive population are 
evident from the differing responses to current injections. 
as LMX1A, LMX1B, NGN2, MASH1, PITX3, together with the 
expression of nestin, vimentin, and radial glia markers (such as 
3CB2)). The expression of functional properties typical of A9-DAn 
in the progeny of hVMl cells further substantiates this view 
(present work and [34-36]). Moreover, among calcium binding 
proteins, only calretinin is expressed in TH+ neurons, but not 
calbindin or parvalbumin typical of ventral tegmental areas DAn 
(E.G.Seiz unpublished). Regarding developmental stages, to con-
sider the hVMl cells as VM DAn precursors is not in conflict with 
the gestational age of the fetus from which they were derived (10 
weeks post conception (PC) [34]). This age is roughly equivalent 
to E14 in mice, a time when TH neurogenesis is considered over 
[69]. However, seminal studies indicate that, in humans, neuro-
genesis is protracted in time, peaking during PC weeks 6.5 to 8 
and finishing by PC week 10-11, a stage where newborn TH+ 
neurons are still present in the ventricular zone and have not yet 
migrated to the mantle zone [70]. Furthermore, VM dopamine 
content in human embryos continuously increases well beyond 
PC week 10 [71]. 
When mitogens are withdrawn the cells start to differentiate, and 
the percentage of nestin or Ki-67 positive cells quickly decreases to 
20-30% by one-two weeks (Supplementary information Fig. 2), 
matching what has been described for FB-derived hNSl cells 
[42,72], and human cortical, striatal and VM neurosphere cultures 
[26,63]. Nestin+ cells only disappeared completely by d30, enfor-
cing the view that hNSCs require long differentiation times in vitro 
to mature (present work and see also [26,40,63]). The forced 
expression of Bcl-XL did not alter the down-regulation of these 
markers (Supplementary information Fig. 2). 
For neurogenesis to take place a set of proneural genes must be 
activated early during differentiation. Here we have studied 
MASH1, NGN2 and MSX1, essential for VM DAn generation 
(NEUROD1 was studied in Ref. [34]). MASH1 cooperates in a 
permissive manner in the generation of VM DAn, both in rodents 
and humans [23,27,46,47]. MSX1 prevents alternative cell fates 
through the repression of Nl<x6.1 and activates Ngn2 expression 
[6,24,43,45]. In the case of the human brain, there is no information 
in the literature about MSX1 expression, but for the lack of effect of 
its over-expression in the NGC-407 cell line of human VM 
precursors. However, in this cell line, endogenous levels of MSX1 
were not studied [61]. NGN2 is essential for the conversion of 
Otx2+ precursors into Nurrl+ postmitotic DAn, and its ablation 
dramatically reduces VM DAn numbers [6,17,18,44,46,68]. For the 
case of MASH1 and NGN2 we have reproduced previous data 
[34,36] which, together with the data on MSX1 (Fig. 2), indicate 
that these proneural genes are expressed in hVMl cells, following 
the expected time course, being MSX1 and NGN2 transiently 
activated. As discussed below, the forced expression of Bcl-XL 
profoundly alters the expression of MSX1 and NGN2. 
Activation of developmental pro-dopaminergic genes 
Regionally specified (EN1, OTX2) and neuron committed (MASH1, 
MSX1 and NGN2) precursors (Figs. 1 and 2) must activate genes 
required for the development of a correct A9-DA phenotype, at a 
time in the mouse when the cells exit the cell cycle [21,22]. Nurrl 
expression in the mouse (cooperating with Pitx3) is critical for the 
acquisition of the correct DA phenotype (that requires co-expres-
sion of TH, AADC, VMAT2 and DAT) [17,22,73,74]. In relation to 
LMX1B, loss of function studies indicate that is required for the 
maintenance of VM DAn [75], and more recently it has been 
involved in patterning [12,18,76]. hVMl cells activate NURR1 and 
LMX1B during the first week of differentiation (Fig. 3), in parallel to 
cell cycle exit (Supplementary information Fig. 2), and prior to the 
blow of TH expression, as temporally expected and normally occurs 
during mouse and human development. PITX3 expression, 
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Fig. 8 - Dopamine transporter (DAT) activity in differentiated cells. (A) In vivo studies of DAT activity by ASP+ labeling in primary 
VM cultures (d7) and hVMl and hVMl Bcl-XL cells (d30), in the presence or absence of NMF (10 uM) to block DAT activity and 
visualize speciflc transport via DAT. Fluorescence confocal microscopy images were collected (scale bar=20 urn). Cells with a 
functional DAT are seen in red. (B) Functional assay of DAT detected by 6-OH-DA induced toxicity. hVMl and hVMl Bcl-XL cells 
(30d) were treated with 6-OHDA (50 mM) in the presence or absence of NMF for 2 day, and stained for TH. Each experiment was 
performed in triplicate and analyzed by one way ANOVA and Tukey's post hoc test (**p<0.01, ***p<0.001 6-OHDA vs 6-
OHDA+NMF treated cultures; +H-p< 0.001 vs untreated cultures). (C) Direct functional assay of DAT activity by [3H] dopamine 
uptake. The data correspond to DAT-mediated speciflc transport, calculated by subtracting the non-speciflc uptake (determined 
in parallel NMF treated cultures). Results are expressed per single TH+ cell, counted in sister, stained cultures. There are not 
significant differences between cultures. Results are mean+SEM (n=6) ANOVA, posthoc Tukey test). 
however, did not activate, possibly explaining a lower-than-possi-
ble yield of DAn in control cells. The expression levels of LMX1B 
and NURR1, and most notably that of PITX3, are enhanced after 
forced Bcl-XL expression (Fig. 3B), what may be of critical impor-
tance to enhance DAn generation (see the Discussion section). 
Maturation, function and maintenance of DAn 
Consistent with our previous reports showing that DAn from hVMl 
cells can synthesize and release DA after depolarization [34-36], 
here we show that the genes needed for DA synthesis (TH, AADC 
and GTPCH1) are in fact expressed during differentiation (Figs. 1, 3 
and 4, S3). The electrophysiological data (showing active neurons) 
we present here for differentiated Bcl-XL hVMl cells largely 
correspond to those previously reported for the control hVMl cell 
line [40]. Though these neuronal electrophysiological properties 
seem to be relatively immature, it is possible that with longer 
differentiation times, or upon grafting, the cells may develop into 
more functionally mature neurons. This notion is partly supported 
by the observed tendency to an increase in membrane potential 
over time. Nevertheless, some of the properties exhibited by the 
cells (high input resistance, trains of action potentials, and long 
duration action potentials are typical of A9 SNpc DAn). In this 
context, Lepski et al. [78] have also reported that telencephalic 
human neural precursors require about six weeks of in vitro 
differentiation to complete their electrophysiological maturation. 
In the present study we have also generated detailed data on 
the correct activation of genes essential for A9-DAn function 
(DAT, VMAT2, DRD2 and GIRK2, Fig. 4B), which gradually 
increased over the month of differentiation studied, again 
indicating a slow maturation. Furthermore, we studied DAT 
activity by three independent means, and consistently found 
that there is an active DA transport in the differentiated DAn 
(Fig. 7), not different from that in primary neurons. Morpholo-
gically, TH+ neurons did not substantially differ from those in 
primary culture (Fig. 6). In summary, DAn generated from hVMl 
precursors express all genes needed for an A9 type DAn to be 
functional, available data indicate a high degree of both mor-
phological and functional maturation of the obtained DAn. Bcl-XL 
effects on maturation are marginal, as discussed later. 
EN1, LMX1B, NURR1 and PITX3 are not only involved in 
development, but also in the survival/maintenance of functional 
A9-DAn ([50-54] reviewed in [6,15,24,49,77]). In control hVMl 
cells the expression levels of these genes first increase during 
differentiation (but for PITX3), to later return to values close to 
basal levels (Fig. 3A and Fig. 5A). This may explain why the 
percentage of TH+ neurons decreased from 12 to 11% (d7-dl2), 
down to 8% (d30) (Fig. 1C). The lack of up-regulation of PITX3 
may also contribute to this decline, since it is crucial for DAn 
maintenance [6,22,49]. In sum, these data would point to a 
compromised maintenance of the DAn in the long perspective, 
although their morphology does not differ from that of the TH+ 
cells in primary cultures (Fig. 6, S4) and they are still functional 
(Figs. 7 and 8, and Ref. [40]). Acknowledgments 
Integration of Bcl-XL effects 
Bcl-XL has been described to exert multiple functions in hNSCs, 
by molecular and cellular mechanisms involving apoptosis, 
changes in gene expression, control of cell cycle duration, and 
expansion of intermediate progenitors [34,36] Bcl-XL has been 
shown to act in FB and VM hNSCs in a dose-response fashion, 
conclusion validated by interfering RNA studies (such as those in 
[78] ). In the case of VM, Bcl-XL enhances the survival of A9-DAn, 
both in vitro and in vivo [35,36], and rescues the neurogenic 
potential of hVMl cells lost with passaging [36]. Those studies 
focused on cell death counteraction (reduced LDH release, 
Annexin-V+ or caspase-3+ cells, DNA fragmentation). DA synth-
esis was also enhanced, as expected by the increased number of 
TH+ cells generated. In the present study we have conducted a 
detailed long-term study of gene expression changes to explain 
further the Bcl-XL-induced enhanced generation of DAn. Present 
data indicate that Bcl-XL has a dramatic effect in MSX1 temporal 
expression, anticipating it, and increasing the net levels of MSX1 
and NGN2, in comparison to control cells (Fig. 2, see also 
Ref. [36]. At later stages, NURR1 is also enhanced, but most 
importantly, PITX3 activation is rescued (Fig. 4). Altogether, these 
gene expression changes (plus a small, 3-fold increase in OTX2 
expression, Supplementary information Fig. 1), are sufficient to 
explain the enhanced number of TH+ neurons generated and TH 
mRNA levels at all times studied (Figs. 1, 3 and 4). Note that by 
d7, TH mRNA levels increase by 4-fold (Fig. 3B, 4Aii), whereas the 
number of TH+ cells is only doubled (Fig. 1C). This, together with 
the increase in the expression of AADC and GTPCH1 (Fig. S2B), 
would suggest an enhanced dopaminergic phenotype. However, 
one cannot affirm that the cells are more mature in the presence 
of elevated levels of Bcl-XL. Long-term data on expression of 
function-related genes (Fig. 4) only indicate that the cells might 
mature faster, and that by d30 Bcl-XL prevents the loss of the DA 
phenotype that occurs in control cells (at least when the data are 
normalized to TH mRNA, Fig. 4C). In addition, electrophysiology 
(Fig. 7), DAT activity determinations (Fig. 8), and morphological 
data (Fig. 6) also indicate that Bcl-XL does not accelerate 
functional maturation in vitro. 
Conclusion 
In the present work we provide evidence demonstrating that VM 
hNSCs with the capacity to generate functional A9 DAn can be 
propagated in culture (at the expense of v-myc), while retaining 
their patterning. These precursors resume their developmental 
instructions during differentiation, offering a stable and repro-
ducible source of functional DAn for basic developmental studies, 
but also applied research in the fields of drug screening and cell 
therapy. The forced expression of Bcl-XL results in an increased 
yield of DAn from VM hNSCs via cell death counteraction 
[36], but also enhancing neuron generation and maintenance 
(present work). 
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Supplementary data associated with this article can be found in the 
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